Used in targeted cancer therapy, particularly for non-small cell lung cancer with specific EGFR mutations. It selectively inhibits mutant forms of EGFR, including the T790M resistance mutation, while sparing wild-type EGFR, reducing side effects. This makes it effective in patients who have developed resistance to first-generation EGFR inhibitors. Its design allows for sustained target inhibition and improved therapeutic outcomes in refractory cases.